PENTRA~RBodies: Rapid Discovery of Highly Potent Femto- To Low Picomolar Antibody Fragments

摘要

Delenex, a biotech company dedicated to the discovery and development of therapeutic antibody fragments, develops small, highest potency PENTRA~RBodies directed against inflammation-associated targets. High femtomolar to low picomolar potencies are obtained without lengthy affinity maturation. PENTRA~RBodies offer a number of advantages over IgGs such as tissue penetration, reduced side-effects due to the absence of the Fc portion, rapid onset of action and rapid clearance.